NO991701L - HIV og cancer behandling - Google Patents

HIV og cancer behandling

Info

Publication number
NO991701L
NO991701L NO991701A NO991701A NO991701L NO 991701 L NO991701 L NO 991701L NO 991701 A NO991701 A NO 991701A NO 991701 A NO991701 A NO 991701A NO 991701 L NO991701 L NO 991701L
Authority
NO
Norway
Prior art keywords
hiv
cancer
herbicide
fungicide
virus
Prior art date
Application number
NO991701A
Other languages
English (en)
Norwegian (no)
Other versions
NO991701D0 (no
Inventor
James Berger Camden
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of NO991701D0 publication Critical patent/NO991701D0/no
Publication of NO991701L publication Critical patent/NO991701L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
NO991701A 1997-05-16 1999-04-09 HIV og cancer behandling NO991701L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4672697P 1997-05-16 1997-05-16
PCT/US1997/021564 WO1998051303A1 (en) 1997-05-16 1997-11-26 Hiv and cancer treatment

Publications (2)

Publication Number Publication Date
NO991701D0 NO991701D0 (no) 1999-04-09
NO991701L true NO991701L (no) 2000-01-17

Family

ID=21945046

Family Applications (1)

Application Number Title Priority Date Filing Date
NO991701A NO991701L (no) 1997-05-16 1999-04-09 HIV og cancer behandling

Country Status (19)

Country Link
EP (1) EP0954309A1 (zh)
JP (1) JP2000510156A (zh)
KR (1) KR20000049064A (zh)
CN (1) CN1254281A (zh)
AR (1) AR009968A1 (zh)
AU (1) AU7402998A (zh)
BR (1) BR9712981A (zh)
CA (1) CA2268848A1 (zh)
CO (1) CO5070657A1 (zh)
CZ (1) CZ124999A3 (zh)
HU (1) HUP9904092A3 (zh)
IL (1) IL129351A0 (zh)
NO (1) NO991701L (zh)
PE (1) PE11499A1 (zh)
PL (1) PL335160A1 (zh)
SK (1) SK46999A3 (zh)
TR (1) TR199901530T2 (zh)
WO (1) WO1998051303A1 (zh)
ZA (1) ZA979095B (zh)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6177460B1 (en) 1995-04-12 2001-01-23 The Procter & Gamble Company Method of treatment for cancer or viral infections
US6262093B1 (en) 1995-04-12 2001-07-17 The Proctor & Gamble Company Methods of treating cancer with benzimidazoles
US6479526B1 (en) 1995-04-12 2002-11-12 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of viruses and cancers
US5770616A (en) 1995-06-07 1998-06-23 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of cancers
US6265427B1 (en) 1995-06-07 2001-07-24 The Proctor & Gamble Company Pharmaceutical composition for the method of treating leukemia
US6686391B2 (en) 1995-08-04 2004-02-03 University Of Arizona Foundation N-chlorophenylcarbamate and N-chlorophenylthiocarbamate compositions
US5900429A (en) 1997-01-28 1999-05-04 The Procter & Gamble Company Method for inhibiting the growth of cancers
US6506783B1 (en) 1997-05-16 2003-01-14 The Procter & Gamble Company Cancer treatments and pharmaceutical compositions therefor
US6245789B1 (en) 1998-05-19 2001-06-12 The Procter & Gamble Company HIV and viral treatment
JP2002537327A (ja) * 1999-02-26 2002-11-05 ナプロ バイオセラピューティクス，インコーポレイテッド 前立腺癌の治療レジメ
CA2366697A1 (en) * 1999-02-26 2000-08-31 Larry Helson Treatment regimen for hormone-sensitive cancers
US6423734B1 (en) 1999-08-13 2002-07-23 The Procter & Gamble Company Method of preventing cancer
AU2001286744A1 (en) * 2000-08-25 2002-03-04 Beth Israel Deaconess Medical Center Compounds and methods for inhibiting neuronal cell death
US6407105B1 (en) * 2000-09-26 2002-06-18 The Procter & Gamble Company Compounds and methods for use thereof in the treatment of cancer or viral infections
US6380232B1 (en) 2000-09-26 2002-04-30 The Procter & Gamble Company Benzimidazole urea derivatives, and pharmaceutical compositions and unit dosages thereof
US6462062B1 (en) 2000-09-26 2002-10-08 The Procter & Gamble Company Compounds and methods for use thereof in the treatment of cancer or viral infections
US6608096B1 (en) 2000-09-26 2003-08-19 University Of Arizona Foundation Compounds and methods for use thereof in the treatment of cancer or viral infections
EP1330441A2 (en) * 2000-09-26 2003-07-30 The University of Arizona Foundation Benzimidazoles and methods for use thereof in the treatment of cancer or viral infections
AU2002239395A1 (en) * 2000-11-01 2002-06-03 The Procter And Gamble Company Hiv treatment with benzimidazoles
JP2004115397A (ja) * 2002-09-25 2004-04-15 Fuji Photo Film Co Ltd 血管疾患治療薬を含むリポソーム
AU2005313839B2 (en) * 2004-12-06 2010-03-11 Pitney Pharmaceuticals Pty Limited Treatment for cancer
PT1830847E (pt) 2004-12-06 2015-02-05 Pitney Pharmaceuticals Pty Ltd Tratamento para o cancro
US7727967B2 (en) * 2006-02-24 2010-06-01 Boise State University Cyanooxime inhibitors of carbonyl reductase and methods of using said inhibitors in treatments involving anthracyclines
WO2009043093A1 (en) * 2007-10-04 2009-04-09 Newsouth Innovations Pty Limited Hif inhibition
CN101643729B (zh) * 2008-08-07 2011-12-28 复旦大学 核酸分子nrn1sr22及其在制备抗癌药物中的应用
EP3119768B1 (en) 2014-03-16 2019-07-31 Hadasit Medical Research Services And Development Ltd. 3,4-bromo or -sulfonate substituted 1h-pyrrole-2,5-dione derivatives as type iii deiodinase (dio3) inhibitors for treating depressions and cancer
CN105418711A (zh) * 2015-11-06 2016-03-23 山东大学 一种α-L-鼠李糖苷酶在制备羟基脲糖苷衍生物中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI9420017B (sl) * 1993-03-31 2003-12-31 Merck & Co. Inc. Inhibitorji proteaze hiv-a v farmacevtskih kombinacijah za zdravljenje aids-a
US5665713A (en) * 1995-04-12 1997-09-09 Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of viruses and cancers
US5656615A (en) * 1995-04-12 1997-08-12 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of cancers and viruses in mammals
TR199701151T1 (xx) * 1995-04-12 1998-03-21 The Procter & Gamble Company Vir�sler ve kanserlerin geli�mesini �nlemeye mahsus, N-klorofenil karbamatlar� ve N-klorofeniltiokarbamatlar� i�eren bir farmas�tik bile�im.
HUP9903420A3 (en) * 1995-08-04 2001-12-28 Procter & Gamble Use of fluconazole for the preparation of pharmaceutical compositions, inhibiting the growth of cancers and treating viral infections

Also Published As

Publication number Publication date
HUP9904092A3 (en) 2000-07-28
BR9712981A (pt) 2000-04-18
TR199901530T2 (xx) 1999-10-21
NO991701D0 (no) 1999-04-09
WO1998051303A1 (en) 1998-11-19
PL335160A1 (en) 2000-04-10
CN1254281A (zh) 2000-05-24
AR009968A1 (es) 2000-05-17
CO5070657A1 (es) 2001-08-28
ZA979095B (en) 1998-05-11
EP0954309A1 (en) 1999-11-10
PE11499A1 (es) 1999-03-01
CZ124999A3 (cs) 1999-09-15
AU7402998A (en) 1998-12-08
JP2000510156A (ja) 2000-08-08
IL129351A0 (en) 2000-02-17
HUP9904092A2 (hu) 2000-04-28
CA2268848A1 (en) 1998-11-19
SK46999A3 (en) 2000-05-16
KR20000049064A (ko) 2000-07-25

Similar Documents

Publication Publication Date Title
NO991701L (no) HIV og cancer behandling
BG50372A3 (en) Fungicidal composition a method of combating fungus
BRPI0410040B1 (pt) combinações de substâncias ativas que apresentam propriedades nematicidas, inseticidas e fungicidas e sâo baseadas em compostos de trifluorbutenila
ATE142423T1 (de) Wässrige dispersionen von sulfonylharnstoffderivaten
NO974696L (no) Farmasöytisk preparat inneholdende N-klor-fenylkarbamater og N-klorfenyltiokarbamater for inhibering av vekst av virus og cancer
Maragos et al. Striatal damage and oxidative stress induced by the mitochondrial toxin malonate are reduced in clorgyline-treated rats and MAO-A deficient mice
EP3115394B1 (en) Antiviral agent
Reuvers et al. Potential use of nitrofurans in radiotherapy
Shcherbyna et al. The research of 1, 2, 4-triazole derivatives hepatoprotective activity under tetracycline and infectious hepatitis
CN109805023A (zh) 一种杀菌组合物
KR20190032209A (ko) 식물바이러스 방제용 조성물 및 이의 용도
Hudson et al. The efficacy of amantadine and other antiviral compounds against two salmonid viruses in vitro
US10624892B2 (en) Agent against fungal infections
JP7277476B2 (ja) アレキシジンジヒドロクロリドと五硼酸ナトリウム五水和物との組み合わせを含む化学療法剤
Keefer Broad-Spectrum Anti-Cancer Activity of O 2-Arylated Diazeniumdiolates
DK165100B (da) Phosphatidholdigt, fungicidt praeparat, dets fremstilling og anvendelse
NO20025898L (no) Fremgangsmater og tilhorende preparater for a oke overlevelsen av akvatiske dyr og andre dyr som utsettes for et akvatisk virus, birnavirus eller annet RNAvirus
CN102972408B (zh) 含三唑酮和氟啶酰菌胺的杀菌组合物
TH43872A (th) เอชไอวีและการรักษามะเร็ง
SU638235A3 (ru) Гербицидный состав
Anaso et al. Assessment of loss in yield due to sorghum downy mildew (Peronosclerospora sorghi) of maize in Nigerian guinea savanna
SU1389702A1 (ru) Способ обработки сем н перед посевом
Kuznetsova et al. Comparative Action of Salsoline, Salsolidine, and Related Compounds on KML Tissue Culture and Animal Tumor Strains.
Ghosh et al. Field evaluation of some new insecticides against brown planthopper Nilaparvata lugens (stål) in rice
Somers The specificity of fungicides

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application